Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.

KA, Papp; JF, Merola; AB, Gottlieb; CEM, Griffiths; N, Cross; L, Peterson; C, Cioffi; A, Blauvelt

doi:10.1016/j.jaad.2018.03.037

Public

Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.

Shared by NobleBlocks on Mar 30, 2018 • 12:00 AM UTC

Authors:

Papp KA

Merola JF

Gottlieb AB

Abstract

Background Neutralizing interleukin (IL) 17F in addition to IL-17A might provide a more complete and specific approach to inhibiting inflammation.Objective Assess the efficacy and safety of bimekizumab, a monoclonal antibody that potently and selectively neutralizes IL-17A and IL-17F, in patients wi...

Subject

Safety

efficacy

Randomized Clinical Trial

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!